Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)(Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel))

概要

基本信息

药物类型

细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

肿瘤

在研适应症-

非在研适应症

实体瘤

原研机构

Universitair Ziekenhuis Brussel

在研机构-

非在研机构

Universitair Ziekenhuis Brussel

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床试验

NCT03707808

/ Completed临床1期IIT

Phase I Clinical Trial on Intratumoral Administration of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Avelumab and Ipilimumab in Combination With Intravenously Administered Nivolumab

This phase I trial aims at investigating a new combinatorial immunotherapy regimen using intratumoral injection of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the PD-L1 blocking mAb avelumab. Concomitantly, nivolumab (a PD-1 blocking mAb) will be administered intravenously.

开始日期2018-01-29

申办/合作机构

Universitair Ziekenhuis Brussel

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床结果

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的转化医学

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床2期	比利时	Universitair Ziekenhuis Brussel	2018-01-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03707808 (ESMO2024) 人工标引	临床1期	难治性黑色素瘤	6	Autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with AS01B plus ipilimumab (IPI) and nivolumab (NIVO)	(襯憲鹽築鹹襯獵醖襯夢) = Treatment related adverse events (TRAE) included transient grade 1/2 injection site reactions and constitutional symptoms. One pt experienced a grade 3 systemic inflammatory syndrome with a lymphocytic peritoneal exudate (responsive to corticosteroids). There were no grade 4-5 TRAE. 齋鏇願糧鹹蓋鬱積築鏇 (醖夢構齋積願構鑰獵鏇 )	积极	2024-09-14
NCT03707808 (Pubmed) 人工标引	临床1期	难治性黑色素瘤 CD1c (BDCA-1) \| CD141 (BDCA-3)	8	autologous CD1c (BDCA-1)+ myDCASipilimumablognivolumab(BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells + ipilimumab + intravenous nivolumab	(襯膚餘餘構艱廠鬱鹹網) = 鹽觸齋齋餘膚衊糧淵遞選顧範鏇製淵齋壓選餘 (製齋築廠糧構鬱窪膚鏇 ) 更多	积极	2024-01-11
NCT03707808 (SITC 12022 \| SITC 22022) 人工标引	临床1期	BRAF V600 突变阳性黑色素瘤 BRAF V600	8	CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel)+nivolumab+ipilimumab	(壓簾糧艱鹹壓鏇襯夢蓋) = 遞餘製簾鑰淵積簾構顧構憲壓鬱廠鑰衊廠餘壓 (獵顧淵憲構鏇襯鹽願醖, 5.193 ~ 15.007) 更多	积极	2022-11-01
NCT03707808 (ASCO 12019 \| ASCO 22019) 人工标引	临床1期	HR阳性/HER2低表达实体瘤二线	6	ipilimumab+Avelumab+Nivolumab+Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells	(淵憲淵範鹽醖夢簾繭鑰) = transient G 2 local pain at injection site in 2 pts, G1 pruritus in 2 pts, G2 pneumonitis in 1 pt, G1 rash in 1 pt, pruritus and redness of the skin overlaying the injected lesion in 1 pt 簾選蓋鑰選餘選築簾繭 (鬱糧遞選齋餘繭遞觸鹹 ) 更多	积极	2019-05-31